Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 4, 2011, Pages 380-391

  Bartha, Eva ^a,b   Solti, Izabella ^a   Szabo, Aliz ^a   Olah, Gabor ^b   Magyar, Klara ^a   Szabados, Eszter ^a   Kalai, Tamas ^a   Hideg, Kalman ^a   Toth, Kalman ^a   Gero, Domokos ^b   Szabo, Csaba ^b   Sumegi, Balazs ^a   Halmosi, Robert ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

cardiomyopathy; doxorubicin; echocardiography; intracellular signaling

Indexed keywords

2 [(2 PIPERIDINE 1 YLETHYL)THIO]QUINAZOLIN 4(3H) ONE; 2 [2 (1 PIPERIDINYL)ETHYLTHIO] 4(3H) QUINAZOLINONE; BRAIN NATRIURETIC PEPTIDE; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA; TEMPOL; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHR1; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GRAVIMETRY; HEART FAILURE; HEART MUSCLE CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEART FAILURE; HSP72 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MYOCYTES, CARDIAC; PHOSPHORYLATION; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; RATS; SPIN LABELS;

EID: 80053990951     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318225c21e     Document Type: Article

References (46)

1. Hideg K, Kálai T. Novel antioxidants in anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:160-164. (Pubitemid 47339865)
2. Neilan TG, Jassal SD, Scully MF, et al. Iloprost attenuates doxorubicininduced cardiac injury in a murine model without compromising tumor suppression. Eur Heart J. 2006;10:1251-1256.
3. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem. 2008;6:278-281.
4. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23:15-25. (Pubitemid 44950185)
5. Chae HJ, Kim HR, Kim DS, et al. Saeng-Ji-Hwang has a protective effect on adriamycin-induced cytotoxicity in cardiac muscle cells. Life Sci. 2005; 76:2027-2042.
6. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys. 1999;368:421-428. (Pubitemid 29406570)
7. Deres P, Halmosi R, Toth A, et al. Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. J Cardiovasc Pharmacol. 2005;45:36-43. (Pubitemid 40039753)
8. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther. 2002;300:862-867. (Pubitemid 34164989)
9. Szenczi O, Kemecsei P, Holthuijsen MFJ, et al. Poly(ADP-ribose)polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol. 2005;69:725-732. (Pubitemid 40248615)
10. Pacher P, Liaudet L, Mabley JG, et al. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med. 2006;17:369-375.
11. Graziani G, Szabó C. Clinical perspectives of PARP inhibitors. Pharmacol Res. 2005;52:109-118. (Pubitemid 40725605)
12. Zhang YW, Shi J, Li YJ, et al. Cardiomyocyte death in doxorubicininduced cardiotoxicity. Arch Immunol Ther Exp. 2009:57:435-445.
13. Palfi A, Toth A, Kulcsar Gy, et al. The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose)polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts. J Pharmacol Exp Ther. 2005;15:273-282. (Pubitemid 41380521)
14. Moens AL, Takimoto E, Tocchetti CG, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 2008;117:2626-2636.
15. Hideg K, Kálai T, Sümegi B. Quinazoline derivates and their use for preparation of pharmaceutical compositions having PARP-Enzyme inhibitory effect. WO 2004/096779, Hungarian Patent PO301173.
16. Palfi A, Toth A, Hanto K, et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway. J Mol Cell Cardiol. 2006;41:149-159. (Pubitemid 43946965)
17. Park JB, Touyz RM, Chen X, et al. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2002;15:78-84. (Pubitemid 34102277)
18. Wang J, Liu X, Sentex E, et al. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H2277-H2287. (Pubitemid 36622442)
19. Salemi VMC, Bilate AMB, Ramires FJA, et al. Reference values from Mmode and Doppler echocardiography for normal Syrian hamsters. Eur J Echocardiogr. 2005;6:41-46. (Pubitemid 40123708)
20. Christiansen S, Autschbach R. Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg. 2006;30:611-616. (Pubitemid 44404103)
21. Nishio M, Sakata Y, Mano T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail. 2008;5:446-453.
22. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69:318-328. (Pubitemid 43098788)
23. Neilan TG, Jassal DS, Perez-Sanz TM, et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J. 2006;27:1868-1875. (Pubitemid 44297395)
24. Arques S, Roux E, Luccioni R. Current clinical application of spectral tissue Doppler echocardiography (E/E# ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function. Cardiovasc Ultrasound. 2007; 26:5-16.
25. Broberg CS, Pantely GA, Barber BJ, et al. Validation of the myocardial performance index by echocardiography in mice: a noninvasive measure of left ventricular function. J Am Soc Echocardiogr. 2003;8:814-823. (Pubitemid 37391008)
26. Fan GC, Zhou X, Wang X, et al. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res. 2008;103:1270-1279.
27. Yamamoto Y, Hoshino Y, Ito T, et al. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardivasc Res. 2008;79:89-96. (Pubitemid 351881941)
28. Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Patents. Cardiovasc Drug Discov. 2006; 1:1-20.
29. Burgering BMT, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689-701. (Pubitemid 38040447)
30. Solit DB, Basso AD, Olshen AB, et al. Inhibition of heat shock protein 90 functions down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003;63:2139-2144. (Pubitemid 36538618)
31. Shinohara T, Takahashi N, Kohno H, et al. Mitochondria are targets for geranylacetone-induced cardioprotection against ischemia-reperfusion in the rat heart. Am J Physiol Heart Circ Physiol. 2007;293:H1892-H1899. (Pubitemid 47367240)
32. Taniike M, Yamaguchi O, Tsujimoto I, et al. Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy. Circulation. 2008;117:545-552.
33. Qin F, Liang MC, Liang C. Progressive left ventricular remodeling, myocyte apoptosis, and protein signaling cascades after myocardial infarction in rabbits. Biochim Biophys Acta. 2005;3:499-513. (Pubitemid 40804762)
34. Kacimi R, Gerdes AM. Alterations in G protein and MAP Kinase signaling pathways during cardiac remodeling in hypertension and heart failure. Hypertension. 2003;41:968-977. (Pubitemid 36418474)
35. Wang Y. Mitogen-activated protein kinase in heart development and diseases. Circulation. 2007;116:1413-1423. (Pubitemid 47417568)
36. Kang YJ, Zhou ZX, Wang GW, et al. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem. 2000;18:13690-13698. (Pubitemid 30257439)
37. Takeishi Y, Bhagwat A, Ball NA, et al. Effect angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol. 1999;276:H53-H62. (Pubitemid 29065622)
38. Haddad GE, Coleman BR, Zhao A, et al. Regulation of atrial contraction by PKA and PKC during development and regression of eccentric cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2005;288:695-704.
39. Koide Y, Tamura K, Suzuki A, et al. Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salts-sensitive rats. Hypertens Res. 2003;26:421-426. (Pubitemid 36701684)
40. Steinberg R, Harari OA, Lidington EA, et al. A protein kinase Ce/antiapoptotic kinase signalling complex protects human vascular endothelial cells against apoptosis through induction of BCL-2. J Biol Chem. 2007; 282:32288-32297. (Pubitemid 350106473)
41. Szabó C. Cardioprotective effects of poly(ADP-ribose)polymerase inhibition. Pharmacol Res. 2005;52:34-43.
42. Mukhopadhyay P, Rajesh M, Bátkai S, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009;296:H1466-H1483.
43. Soriano FG, Nogueira AC, Caldini EG, et al. Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med. 2006;34:1073-1079.
44. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repairdeficient malignant glioma xenograft. Mol Cancer Ther. 2005;4:1364-1368.
45. Gien LT, Mackay HJ. The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer. J Oncol. 2010. [Epub ahead of print].
46. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293-301.